Previous Close | 3.19 |
1-Year Change | -21.04% |
6-Months Change | -25.81% |
3-Months Change | -41.14% |
Moving Avg (50d) | 3.4376 |
Moving Avg (200d) | 4.8504 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.13B |
Beta (3-Years) | 2.5 |
Revenue Growth (ttm) | -0.18% |
Net Profit Margin (ttm) | -82377.52% |
Return On Assets (ttm) | -105.92% |
EPS (ttm) | -1.05 |
PE Ratio (ttm) | -3.04 |
Dividend Yield | % |
Asset Description: | ImmunityBio, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2025-02-03 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
3.254 | 3.35 | 3.413 | 3.509 | 3.669 | 3.828 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.